Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy

Area of Science:

• Endocrinology
• Virology
• Metabolic Syndrome

Background:

• HIV-associated lipodystrophy presents as fat redistribution (central and dorsocervical fat), hyperlipidemia, and insulin resistance.
• While serum cortisol is typically normal, elevated cortisol/dehydroepaindrosterone (DHEA) ratios suggest relative hypercortisolism in HIV patients.
• HIV protease inhibitors, common in antiviral therapy, may exacerbate peroxisome dysregulation linked to lipodystrophy.

Purpose of the Study:

• To investigate the efficacy of dehydroepaindrosterone (DHEA) and cyclo-oxygenase (COX) inhibitors in managing HIV-associated lipodystrophy.
• To assess the impact of these supplements on fat redistribution, serum lipids, and insulin resistance in HIV-positive patients.

Main Methods:

• Seven HIV-positive male patients with lipodystrophy received DHEA (100-200 mg/day) alone or in combination with a COX inhibitor (indomethacin or naprosyn).
• Treatment duration was approximately 1 year.
• Outcomes measured included changes in serum lipids, blood glucose levels, and dorsocervical fat accumulation.

Main Results:

• DHEA supplementation alone led to moderation of serum lipids and some improvement in blood sugar.
• The addition of a COX inhibitor resulted in more significant improvements in blood sugar and noticeable decreases in dorsocervical fat.
• All patients experienced some degree of metabolic improvement with the combined therapy.

Conclusions:

• Combined supplementation with dehydroepaindrosterone (DHEA) and cyclo-oxygenase (COX) inhibitors shows promise in managing HIV-associated lipodystrophy.
• These agents may improve peroxisomal function, addressing a key mechanism in the condition's pathophysiology.
• The findings suggest a potential therapeutic strategy for metabolic and fat redistribution issues in HIV patients on antiviral therapy.